APA (7th ed.) Citation

RA, K., S, J., WR, F., CF, S., SV, R., PR, G., . . . Greipp, P. R. (2009). The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and alpha(2)beta interferon versus VBMCP: Results of a phase III Eastern Cooperative Oncology Group Study E5A93. Cancer (0008543X), 115(10), 2155. https://doi.org/10.1002/cncr.24221

Chicago Style (17th ed.) Citation

RA, Kyle, et al. "The Treatment of Multiple Myeloma Using Vincristine, Carmustine, Melphalan, Cyclophosphamide, and Prednisone (VBMCP) Alternating with High-dose Cyclophosphamide and Alpha(2)beta Interferon Versus VBMCP: Results of a Phase III Eastern Cooperative Oncology Group Study E5A93." Cancer (0008543X) 115, no. 10 (2009): 2155. https://doi.org/10.1002/cncr.24221.

MLA (9th ed.) Citation

RA, Kyle, et al. "The Treatment of Multiple Myeloma Using Vincristine, Carmustine, Melphalan, Cyclophosphamide, and Prednisone (VBMCP) Alternating with High-dose Cyclophosphamide and Alpha(2)beta Interferon Versus VBMCP: Results of a Phase III Eastern Cooperative Oncology Group Study E5A93." Cancer (0008543X), vol. 115, no. 10, 2009, p. 2155, https://doi.org/10.1002/cncr.24221.